Use of Bone-Modifying Agents among Medicare Beneficiaries with Multiple Myeloma

Arjun Gupta; Peiqi Wang; Syed Abbas Ali; S. Vincent Rajkumar; Bishal Gyawali; Heidi N. Overton; Martin A. Makary

doi:10.1001/jamaoncol.2019.5426

Use of Bone-Modifying Agents among Medicare Beneficiaries with Multiple Myeloma

Arjun Gupta, Peiqi Wang, Syed Abbas Ali, S. Vincent Rajkumar, Bishal Gyawali, Heidi N. Overton, Martin A. Makary

Hematology

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	296-298
Number of pages	3
Journal	JAMA Oncology
Volume	6
Issue number	2
DOIs	https://doi.org/10.1001/jamaoncol.2019.5426
State	Published - Feb 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2019.5426

Cite this

@article{485dda883fc2424fba4979f405f67972,

title = "Use of Bone-Modifying Agents among Medicare Beneficiaries with Multiple Myeloma",

author = "Arjun Gupta and Peiqi Wang and Ali, {Syed Abbas} and Rajkumar, {S. Vincent} and Bishal Gyawali and Overton, {Heidi N.} and Makary, {Martin A.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Ali reported grants and personal fees from Celgene, personal fees from Bristol-Myers Squibb, grants and personal fees from Aduro Biotech, personal fees from Sanofi, grants and personal fees from Amgen, and grants from Poseida Therapeutics. Dr Overton received funding (grant 5T32CA126607-10) from the National Institutes of Health. Dr Makary receives funding from the Laura and John Arnold Foundation. No other disclosures were reported. 1. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370-381. doi:10.1016/S1470-2045(18)30072-X 2. Chakraborty R, Majhail NS, Anwer F. Denosumab vs zoledronic acid for bone-targeted therapy in multiple myeloma: what are the unanswered questions? JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.1598 3. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment: a prospective 2-year clinical trial. J Bone Miner Res.2019. doi:10.1002/jbmr.3853 4. West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol. 2011;29(9):1095-1098. doi:10.1200/JCO.2010.33.5596 5. Goldstein DA. Denosumab for bone lesions in multiple myeloma: what is its value? Haematologica. 2018;103(5):753-754. doi:10.3324/haematol.2017.185264 6. Gyawali B, Tessema FA, Jung EH, Kesselheim AS. Assessing the justification, funding, success, and survival outcomes of randomized noninferiority trials of cancer drugs: a systematic review and pooled analysis. JAMA Netw Open. 2019; 2(8):e199570. doi:10.1001/jamanetworkopen.2019.9570",

year = "2020",

month = feb,

doi = "10.1001/jamaoncol.2019.5426",

language = "English (US)",

volume = "6",

pages = "296--298",

journal = "JAMA oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - Use of Bone-Modifying Agents among Medicare Beneficiaries with Multiple Myeloma

AU - Gupta, Arjun

AU - Wang, Peiqi

AU - Ali, Syed Abbas

AU - Rajkumar, S. Vincent

AU - Gyawali, Bishal

AU - Overton, Heidi N.

AU - Makary, Martin A.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Ali reported grants and personal fees from Celgene, personal fees from Bristol-Myers Squibb, grants and personal fees from Aduro Biotech, personal fees from Sanofi, grants and personal fees from Amgen, and grants from Poseida Therapeutics. Dr Overton received funding (grant 5T32CA126607-10) from the National Institutes of Health. Dr Makary receives funding from the Laura and John Arnold Foundation. No other disclosures were reported. 1. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370-381. doi:10.1016/S1470-2045(18)30072-X 2. Chakraborty R, Majhail NS, Anwer F. Denosumab vs zoledronic acid for bone-targeted therapy in multiple myeloma: what are the unanswered questions? JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.1598 3. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment: a prospective 2-year clinical trial. J Bone Miner Res.2019. doi:10.1002/jbmr.3853 4. West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol. 2011;29(9):1095-1098. doi:10.1200/JCO.2010.33.5596 5. Goldstein DA. Denosumab for bone lesions in multiple myeloma: what is its value? Haematologica. 2018;103(5):753-754. doi:10.3324/haematol.2017.185264 6. Gyawali B, Tessema FA, Jung EH, Kesselheim AS. Assessing the justification, funding, success, and survival outcomes of randomized noninferiority trials of cancer drugs: a systematic review and pooled analysis. JAMA Netw Open. 2019; 2(8):e199570. doi:10.1001/jamanetworkopen.2019.9570

PY - 2020/2

Y1 - 2020/2

UR - http://www.scopus.com/inward/record.url?scp=85076617304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076617304&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.5426

DO - 10.1001/jamaoncol.2019.5426

M3 - Letter

C2 - 31830210

AN - SCOPUS:85076617304

SN - 2374-2437

VL - 6

SP - 296

EP - 298

JO - JAMA oncology

JF - JAMA oncology

IS - 2

ER -

Use of Bone-Modifying Agents among Medicare Beneficiaries with Multiple Myeloma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this